News
ENTX
1.660
-2.92%
-0.050
Weekly Report: what happened at ENTX last week (0629-0703)?
Weekly Report · 2d ago
Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus
NASDAQ · 06/29 12:32
Weekly Report: what happened at ENTX last week (0622-0626)?
Weekly Report · 06/29 09:07
Entera Bio: Buy Rating Reiterated on De-Risked Oral PTH Platform and FDA-Supported Phase 3 Design; $9 Price Target Maintained
TipRanks · 06/24 10:15
Entera Bio Announces FDA Has Provided Positive Feedback On The Phase 3 Protocol For EB613, The Company's Oral Osteoporosis Tablet
Benzinga · 06/23 12:51
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 06/23 12:05
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 06/22 21:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 06/22 17:05
Reported Earlier: Entera Bio Receives FDA's Positive Feedback For Its Phase 3 Registrational Protocol For EB613 Tablet In Development To Treat Osteoporosis
Benzinga · 06/22 16:32
Entera Bio gets FDA feedback on registrational protocol for EB613
TipRanks · 06/22 14:04
With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For
TipRanks · 06/22 13:30
Weekly Report: what happened at ENTX last week (0615-0619)?
Weekly Report · 06/22 09:08
After Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story?
TipRanks · 06/18 15:00
Entera Bio and Opko Health present preclinical data for oral peptides
TipRanks · 06/16 13:36
Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward Clinical Development
Benzinga · 06/16 12:44
Entera Bio Presents Oral Presentation Titled Transforming Anabolic Treatments For Osteoporosis: New Clinical Data Supports A Single Eb613 Tablet At ENDO 2026 Regarding Phase 1 Data Of EB613 With Forteo
Benzinga · 06/15 12:50
Weekly Report: what happened at ENTX last week (0608-0612)?
Weekly Report · 06/15 09:08
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
Barchart · 06/15 07:45
Weekly Report: what happened at ENTX last week (0601-0605)?
Weekly Report · 06/08 09:08
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
TipRanks · 06/01 13:30
More
Webull provides a variety of real-time ENTX stock news. You can receive the latest news about Entera Bio Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ENTX
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.